kabutan

Cyfuse Biomedical, Apr-Jun (2Q) Ordinary Profit Loss Widens

Thu Aug 14, 2025 3:30 pm JST Earnings

4892 Cyfuse Biomedical K.K. 【J-GAAP】

Earnings Report

Cyfuse Biomedical K.K. <4892> [TSE Growth] announced its financial results after the market closed on August 14th (15:30). The ordinary loss (non-consolidated) for the cumulative second quarter of the fiscal year ending December 2025 (January to June) was a reduced loss of 401 million yen (compared to a loss of 445 million yen in the same period last year).

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the ordinary loss for the July to December period (second half) is expected to expand to a loss of 739 million yen (compared to a loss of 424 million yen in the same period last year).

In the most recent three-month period, from April to June (2Q), the ordinary loss expanded to a loss of 239 million yen (compared to a loss of 222 million yen in the same period last year). The operating profit/loss margin drastically worsened from -2737.5% in the same period last year to -4620.0%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Jan - Jun, 2023 18 -363 -362 -364 -46.7 ー Aug 14, 2023 J-GAAP
Jan - Jun, 2024 18 -448 -445 -447 -56.2 ー Aug 14, 2024 J-GAAP
Jan - Jun, 2025 29 -471 -401 -402 -48.9 ー Aug 14, 2025 J-GAAP
YoY +61.1% -5.1% +9.9% +10.1% +13.0%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jan - Jun, 2025 Guidance ー ー ー ー － 0 Feb 14, 2025 J-GAAP
Jan - Jun, 2025 Results 29 -471 -401 -402 -48.9 0 Aug 14, 2025 J-GAAP
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Jul - Dec, 2024 36 -448 -424 -425 -52.8 0 Feb 14, 2025 J-GAAP
Jul - Dec, 2025 Guidance 273 -748 -739 -740 -77.1 0 Aug 14, 2025 J-GAAP
YoY +658.3% -67.0% -74.3% -74.1% -45.9%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Dec, 2023 61 -697 -586 -589 -75.4 0 Feb 14, 2024 J-GAAP
Dec, 2024 54 -896 -869 -872 -108.3 0 Feb 14, 2025 J-GAAP
Dec, 2025 Guidance 302 -1,219 -1,140 -1,142 -118.9 0 Feb 14, 2025 J-GAAP
YoY +459.3% -36.0% -31.2% -31.0% -9.7%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Apr - Jun, 2024 8 -219 -222 -223 -28.0 -2,737.5 Aug 14, 2024 J-GAAP
Jul - Sep, 2024 8 -226 -217 -217 -27.1 -2,825.0 Nov 14, 2024 J-GAAP
Oct - Dec, 2024 28 -222 -207 -208 -25.8 -792.9 Feb 14, 2025 J-GAAP
Jan - Mar, 2025 24 -240 -162 -162 -19.9 -1,000.0 May 15, 2025 J-GAAP
Apr - Jun, 2025 5 -231 -239 -240 -29.2 -4,620.0 Aug 14, 2025 J-GAAP
YoY -37.5% -5.5% -7.7% -7.6% -4.1%

Related Articles